{"id":"W4289985859","doi":"10.3390/curroncol29080434","title":"Drug Treatment for Advanced Hepatocellular Carcinoma: First-Line and Beyond","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Sorafenib; Medicine; Regorafenib; Lenvatinib; Nivolumab; Ramucirumab; Atezolizumab; Cabozantinib; Ipilimumab; Bevacizumab; Oncology; Internal medicine; Hepatocellular carcinoma; Pembrolizumab; Renal cell carcinoma; Cancer; Immunotherapy; Colorectal cancer; Chemotherapy","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004407783,0.000377877,0.0008258267,0.0005019724,0.0003135587,0.0008725022,0.0004737775,0.0006777234,0.008500864],"category_scores_gemma":[0.000632411,0.00009337733,0.0005255803,0.0005753252,0.0002794139,0.0009094198,0.0005016369,0.001650085,0.00441704],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006882754,"about_ca_system_score_gemma":0.0006999075,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009113064,"about_ca_topic_score_gemma":0.002890489,"domain_scores_codex":[0.9997433,0.00007090809,0.00001994645,0.00003437682,0.00009608376,0.00003545791],"domain_scores_gemma":[0.99963,0.00005607837,0.0000581265,0.00002753067,0.0001331654,0.00009514304],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004122078,0.0002684864,0.001224244,0.002479605,0.0001093996,0.0003999826,0.00007776484,0.0002357623,0.003454515,0.006055991,0.1329857,0.8522963],"study_design_scores_gemma":[0.0001819673,0.0007090452,0.001822254,0.0007070212,0.0000968861,0.001822486,0.00003495712,0.0002998126,0.001501051,0.002356507,0.9904485,0.00001936965],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.008402714,0.9306396,0.00308692,0.01881018,0.003595687,0.0001246514,0.0007706753,0.0003048599,0.03426469],"genre_scores_gemma":[0.09461432,0.8301266,0.006003128,0.02128273,0.004934393,0.0002592668,0.00254882,0.0001295973,0.04010112],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.008500864,"threshold_uncertainty_score":0.02843827,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2562370346035748,"score_gpt":0.4813477896404419,"score_spread":0.2251107550368671,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}